Your browser doesn't support javascript.
loading
Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience.
Marcus, M D; Wilfley, D E; El Ghormli, L; Zeitler, P; Linder, B; Hirst, K; Ievers-Landis, C E; van Buren, D J; Walders-Abramson, N.
Afiliação
  • Marcus MD; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Wilfley DE; Department of Psychiatry, Washington University School of Medicine, St Louis, MO.
  • El Ghormli L; George Washington University, Biostatistics Center, Rockville, MD.
  • Zeitler P; Department of Pediatrics, Section of Endocrinology, University of Colorado School of Medicine, Aurora, CO.
  • Linder B; Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
  • Hirst K; George Washington University, Biostatistics Center, Rockville, MD.
  • Ievers-Landis CE; Rainbow Babies and Children's Hospital, University Hospitals Case Medical Center, Cleveland, OH.
  • van Buren DJ; Department of Psychiatry, Washington University School of Medicine, St Louis, MO.
  • Walders-Abramson N; Department of Pediatrics, Section of Endocrinology, University of Colorado School of Medicine, Aurora, CO.
Pediatr Obes ; 12(4): 337-345, 2017 08.
Article em En | MEDLINE | ID: mdl-27161901
BACKGROUND: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) clinical trial documented that metformin plus rosiglitazone, but not metformin plus lifestyle intervention, provided superior durability of glycemic control relative to metformin monotherapy. OBJECTIVES: We examined weight changes among TODAY participants that completed at least 6 months of treatment, evaluated predictors of lifestyle outcome, and examined whether weight changes were related to cardiometabolic outcomes across treatment arms. METHODS: The 595 youth with type 2 diabetes, (85.1% of randomized participants aged 11-17 years) completed assessments of weight-related and cardiometabolic measures at months 0, 6, 12 and 24. Repeated measures models were used to investigate associations over time. RESULTS: Lifestyle intervention did not enhance outcome relative to metformin alone and no predictors of response to lifestyle treatment were identified. However, changes in percent overweight across treatment arms were associated with changes in multiple cardiometabolic risk factors, and decreases of ≥ 7% in overweight were associated with significant benefits over 24 months. CONCLUSIONS: Although adjunctive intensive lifestyle intervention did not improve weight-related outcomes, weight changes in the full TODAY sample were associated with small, but significant improvements in cardiometabolic status, highlighting the importance of optimizing weight management in youth with T2DM.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tiazóis / Peso Corporal / Diabetes Mellitus Tipo 2 / Hipoglicemiantes / Metformina Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Pediatr Obes Ano de publicação: 2017 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tiazóis / Peso Corporal / Diabetes Mellitus Tipo 2 / Hipoglicemiantes / Metformina Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Pediatr Obes Ano de publicação: 2017 Tipo de documento: Article País de publicação: Reino Unido